IS2789B - Lyfjablöndur sem innihalda mónóamínoxídasa B hemla - Google Patents

Lyfjablöndur sem innihalda mónóamínoxídasa B hemla

Info

Publication number: IS2789B
Authority: IS; Iceland
Prior art keywords: monoamine oxidase; inhibitors; preparations containing; medicinal preparations; containing monoamine
Prior art date: 1995-03-02

Application number

IS4553A

Other languages

English (en)

Other versions

IS4553A (is

Inventor

Francesca Mary Brewer

Edward Stewart Johnson

Anthony Clarke

Original Assignee

Scherer Ltd R P

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-02

Filing date

1997-08-27

Publication date

2012-06-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306612&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2789(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-03-02 Priority claimed from GBGB9504235.4A external-priority patent/GB9504235D0/en

1997-08-27 Application filed by Scherer Ltd R P filed Critical Scherer Ltd R P

1997-08-27 Publication of IS4553A publication Critical patent/IS4553A/is

2012-06-15 Publication of IS2789B publication Critical patent/IS2789B/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Physiology (AREA)
Zoology (AREA)
Nutrition Science (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)

IS4553A 1995-03-02 1997-08-27 Lyfjablöndur sem innihalda mónóamínoxídasa B hemla IS2789B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9504235.4A GB9504235D0 (en)	1995-03-02	1995-03-02	Pharmaceutical compositon
GBGB9517063.5A GB9517063D0 (en)	1995-03-02	1995-08-18	Pharmaceutical composition
PCT/GB1996/000484 WO1996026720A1 (en)	1995-03-02	1996-03-01	Pharmaceutical compositions comprising monoamine oxidase b inhibitors

Publications (2)

Publication Number	Publication Date
IS4553A IS4553A (is)	1997-08-27
IS2789B true IS2789B (is)	2012-06-15

Family

ID=26306612

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4553A IS2789B (is)	1995-03-02	1997-08-27	Lyfjablöndur sem innihalda mónóamínoxídasa B hemla

Country Status (26)

Country	Link
US (3)	US20010021722A1 (is)
EP (1)	EP0814789B2 (is)
JP (1)	JP3273141B2 (is)
CN (1)	CN1171586C (is)
AT (1)	ATE241346T1 (is)
AU (1)	AU702161B2 (is)
BG (1)	BG63862B1 (is)
BR (1)	BR9607057A (is)
CA (1)	CA2214026C (is)
CZ (1)	CZ297382B6 (is)
DE (1)	DE69628415T3 (is)
DK (1)	DK0814789T4 (is)
EE (1)	EE04039B1 (is)
ES (1)	ES2199283T5 (is)
GE (1)	GEP20012374B (is)
HU (1)	HU228852B1 (is)
IS (1)	IS2789B (is)
MX (1)	MX9706647A (is)
NO (1)	NO316804B1 (is)
NZ (2)	NZ302723A (is)
PL (1)	PL183266B1 (is)
PT (1)	PT814789E (is)
SI (1)	SI0814789T2 (is)
SK (1)	SK284383B6 (is)
TR (1)	TR199700878T1 (is)
WO (1)	WO1996026720A1 (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5844003A (en) *	1991-04-04	1998-12-01	Innovations Foundation	Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
WO1996024346A1 (en)	1995-02-10	1996-08-15	The University Of Toronto Innovations Foundation	Deprenyl compounds for treatment of glaucoma
IL115357A (en) *	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
CN1207675A (zh) *	1995-11-06	1999-02-10	萨默塞特药品有限公司	丙炔苯丙胺的经颊和舌下给药法
GB9715082D0 (en) *	1997-07-17	1997-09-24	Scherer Ltd R P	Treatment of attention deficit hyperactivity disorder and narcolepsy
GB9717770D0 (en) *	1997-08-21	1997-10-29	Scherer Ltd R P	Pharmaceutical composition
GB9802088D0 (en) *	1998-01-30	1998-03-25	Scherer Ltd R P	Pharmaceutical products
WO2000064462A1 (en) *	1999-04-21	2000-11-02	Yuyu Industrial Co., Ltd.	Pharmaceutical compositions containing selegiline and ginkgo biloba extract useful for dementia
US20050089502A1 (en) *	2003-08-21	2005-04-28	Todd Schansberg	Effervescent delivery system
CA2588293C (en) *	2004-11-24	2013-07-02	Teva Pharmaceutical Industries Ltd.	Rasagiline orally disintegrating compositions
ZA200704917B (en) *	2004-11-24	2008-11-26	Teva Pharma	Rasagiline orally disintegrating compositions
US7956220B2 (en)	2005-07-01	2011-06-07	Jenrin Discovery	MAO-B inhibitors useful for treating obesity
CN1911211B (zh) *	2006-08-25	2010-04-14	重庆医药工业研究院有限责任公司	雷沙吉兰口服固体制剂
EP1897543A1 (en)	2006-08-30	2008-03-12	Euro-Celtique S.A.	Buprenorphine- wafer for drug substitution therapy
US20070190187A1 (en) *	2006-09-07	2007-08-16	Kneller Bruce W	Formulation for enhanced delivery of phenethylamine
EP2053033A1 (en)	2007-10-26	2009-04-29	Bayer Schering Pharma AG	Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
CN102612363A (zh) *	2009-05-20	2012-07-25	舌交付有限公司	口腔和/或舌下治疗制剂
US8475832B2 (en)	2009-08-07	2013-07-02	Rb Pharmaceuticals Limited	Sublingual and buccal film compositions
CN102048717B (zh) †	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2450332A1 (en) *	2010-10-22	2012-05-09	Bayer Pharma Aktiengesellschaft	Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl)
WO2013175493A1 (en)	2012-04-09	2013-11-28	Cadila Healthcare Limited	Stable oral pharmaceutical compositions
US10292947B2 (en)	2016-03-26	2019-05-21	Dr. Reddy's Laboratories Ltd.	Pharmaceutical compositions for N-propargylamine derivative

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1227447B (de) *	1962-03-30	1966-10-27	Chinoin Gyogyszer Es Vegyeszet	Verfahren zur Herstellung von Phenylisopropylaminen
GB1548022A (en) *	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
CA1097233A (en) *	1977-07-20	1981-03-10	George K. E. Gregory	Packages
US4454158A (en) *	1981-06-01	1984-06-12	Merrell Toraude Et Compagnie	Allyl amine MAO inhibitors
IE53696B1 (en) *	1981-12-02	1989-01-18	Wyeth John & Brother Ltd	Solid shaped articles
EP0252290B1 (en) *	1986-06-10	1992-06-03	CHIESI FARMACEUTICI S.p.A.	Pharmaceutical compositions containing levodopa methyl ester, preparation and therapeutic applications thereof
HU197510B (en) *	1986-12-19	1989-04-28	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
JP2660419B2 (ja) *	1988-04-02	1997-10-08	旭電化工業株式会社	安定化された合成樹脂組成物
US4866046A (en) *	1988-05-31	1989-09-12	Top Laboratories, Inc.	Low-dosage sublingual aspirin
HU208484B (en) *	1988-08-17	1993-11-29	Chinoin Gyogyszer Es Vegyeszet	Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5055303A (en) *	1989-01-31	1991-10-08	Kv Pharmaceutical Company	Solid controlled release bioadherent emulsions
US5079018A (en) *	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
IL92952A (en) *	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5192550A (en) †	1990-05-07	1993-03-09	Alza Corporation	Dosage form for treating central nervous system disorders
GB9017610D0 (en) *	1990-08-10	1990-09-26	Erba Carlo Spa	Antiparkinson mao reversible inhibitor
HU219349B (en) †	1991-12-24	2001-03-28	Yamanouchi Pharma Co Ltd	Intrabuccally disintegrating preparation and production thereof
US5298261A (en) *	1992-04-20	1994-03-29	Oregon Freeze Dry, Inc.	Rapidly distintegrating tablet
US5607691A (en) *	1992-06-12	1997-03-04	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
WO1993025197A1 (en) †	1992-06-12	1993-12-23	Affymax Technologies N.V.	Compositions and methods for enhanced drug delivery
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
CN1207675A (zh) †	1995-11-06	1999-02-10	萨默塞特药品有限公司	丙炔苯丙胺的经颊和舌下给药法

1996
- 1996-03-01 AT AT96904929T patent/ATE241346T1/de active
- 1996-03-01 WO PCT/GB1996/000484 patent/WO1996026720A1/en active IP Right Grant
- 1996-03-01 CZ CZ0270597A patent/CZ297382B6/cs not_active IP Right Cessation
- 1996-03-01 PL PL96322046A patent/PL183266B1/pl unknown
- 1996-03-01 EE EE9700187A patent/EE04039B1/xx unknown
- 1996-03-01 NZ NZ302723A patent/NZ302723A/en not_active IP Right Cessation
- 1996-03-01 ES ES96904929T patent/ES2199283T5/es not_active Expired - Lifetime
- 1996-03-01 AU AU48846/96A patent/AU702161B2/en not_active Expired
- 1996-03-01 SK SK1158-97A patent/SK284383B6/sk not_active IP Right Cessation
- 1996-03-01 BR BR9607057A patent/BR9607057A/pt not_active Application Discontinuation
- 1996-03-01 CN CNB961923032A patent/CN1171586C/zh not_active Expired - Lifetime
- 1996-03-01 GE GEAP19963934A patent/GEP20012374B/en unknown
- 1996-03-01 SI SI9630617T patent/SI0814789T2/sl unknown
- 1996-03-01 EP EP96904929A patent/EP0814789B2/en not_active Expired - Lifetime
- 1996-03-01 NZ NZ329471A patent/NZ329471A/en not_active IP Right Cessation
- 1996-03-01 HU HU9801227A patent/HU228852B1/hu unknown
- 1996-03-01 DK DK96904929T patent/DK0814789T4/da active
- 1996-03-01 CA CA002214026A patent/CA2214026C/en not_active Expired - Lifetime
- 1996-03-01 US US08/894,764 patent/US20010021722A1/en not_active Abandoned
- 1996-03-01 JP JP52610896A patent/JP3273141B2/ja not_active Expired - Lifetime
- 1996-03-01 PT PT96904929T patent/PT814789E/pt unknown
- 1996-03-01 DE DE69628415T patent/DE69628415T3/de not_active Expired - Lifetime
- 1996-03-01 TR TR97/00878T patent/TR199700878T1/xx unknown
1997
- 1997-08-27 IS IS4553A patent/IS2789B/is unknown
- 1997-09-01 NO NO19974010A patent/NO316804B1/no not_active IP Right Cessation
- 1997-09-02 MX MX9706647A patent/MX9706647A/es unknown
- 1997-10-01 BG BG101937A patent/BG63862B1/bg unknown
2003
- 2003-07-01 US US10/610,613 patent/US20040091525A1/en not_active Abandoned
2007
- 2007-09-05 US US11/850,141 patent/US20080187573A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CZ270597A3 (cs)	1998-01-14
US20080187573A1 (en)	2008-08-07
DE69628415D1 (de)	2003-07-03
ATE241346T1 (de)	2003-06-15
BR9607057A (pt)	1998-06-09
WO1996026720A1 (en)	1996-09-06
GEP20012374B (en)	2001-03-25
AU702161B2 (en)	1999-02-18
ES2199283T3 (es)	2004-02-16
NZ329471A (en)	1999-10-28
DK0814789T3 (da)	2003-09-01
EP0814789B2 (en)	2008-01-09
US20040091525A1 (en)	2004-05-13
SI0814789T1 (en)	2003-12-31
EE9700187A (et)	1998-02-16
DE69628415T3 (de)	2008-06-26
CA2214026A1 (en)	1996-09-06
SK284383B6 (sk)	2005-02-04
BG101937A (en)	1998-07-31
NO974010D0 (no)	1997-09-01
NO974010L (no)	1997-10-30
HUP9801227A2 (hu)	1999-06-28
PL322046A1 (en)	1998-01-05
PT814789E (pt)	2003-09-30
JPH10506409A (ja)	1998-06-23
NO316804B1 (no)	2004-05-18
IS4553A (is)	1997-08-27
US20010021722A1 (en)	2001-09-13
HUP9801227A3 (en)	2000-02-28
PL183266B1 (pl)	2002-06-28
CN1178461A (zh)	1998-04-08
SI0814789T2 (sl)	2008-04-30
DE69628415T2 (de)	2004-03-11
TR199700878T1 (xx)	1998-01-21
NZ302723A (en)	1998-04-27
DK0814789T4 (da)	2008-05-19
SK115897A3 (en)	1998-03-04
BG63862B1 (bg)	2003-04-30
CZ297382B6 (cs)	2006-11-15
CA2214026C (en)	2007-10-16
CN1171586C (zh)	2004-10-20
EP0814789B1 (en)	2003-05-28
HU228852B1 (en)	2013-06-28
EP0814789A1 (en)	1998-01-07
JP3273141B2 (ja)	2002-04-08
EE04039B1 (et)	2003-06-16
ES2199283T5 (es)	2008-05-16
AU4884696A (en)	1996-09-18
MX9706647A (es)	1998-06-30

Publication	Publication Date	Title
IS2789B (is)	2012-06-15	Lyfjablöndur sem innihalda mónóamínoxídasa B hemla
ATE525061T1 (de)	2011-10-15	Feste selbst-haftende zusammensetzungen zur topischen behandlung von störungen der mundschleimhaut
ATE153853T1 (de)	1997-06-15	Stabile, orale und absorbierbare therapeutische zusammensetzungen von nadh und nadph
MX9603520A (es)	1998-01-31	Derivados del acido hidroxamico y acido carboxilico, procesos para su preparacion y su uso.
DE60120648D1 (de)	2006-07-27	Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
MY111260A (en)	1999-10-30	Pharmaceutical composition for the treatment of nicotine dependence
DE69802113D1 (de)	2001-11-22	Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
ATE386523T1 (de)	2008-03-15	Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
TR199801229T2 (xx)	1998-09-21	''Metalopeptidaz inhibisyon aktivitesini havi tiol t�revleri
BR0014440A (pt)	2002-06-18	Formulações de liberação controlada oral
TR200102087T2 (tr)	2001-12-21	Yeni morfolinbenzamid tuzları
TR200003451T2 (tr)	2001-04-20	Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları
DE69824410D1 (en)	2004-07-15	Antithrombosemittel
YU87302A (sh)	2006-01-16	Inhibitori 11-beta-hidroksi steroidne dehidrogenaze, tip 1
FI20031793A0 (fi)	2003-12-09	Uusi anti-proliferatiivinen farmaseuttinen koostumus
MD940244A (ro)	1996-01-31	Derivaţi noi ai tetrazolului, procedeu de obţinere a lor şi compoziţie farmaceutică pe baza lor
GT199400048A (es)	1996-01-12	Composicion farmaceutica y proceso para su preparacion